Niagen Bioscience, Inc. current report, 12 November 2019

SEC Filing Summary: ChromaDex Corporation (8-K)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on November 12, 2019. The filing serves to announce the Company's earnings results for the quarter ended September 30, 2019, and to disclose a corporate presentation made available on the Company's website. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CDXC.

Key Financial Metrics

The provided text is a cover sheet and does not contain specific financial data. It references a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) where the actual figures are located. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the period.

Material Changes

No specific material changes in financial condition or operations are detailed in this document. The filing indicates that the Company has released earnings results for the quarter ended September 30, 2019, but the magnitude or direction of any changes versus the prior period is not stated in the text provided.

Guidance, Outlook, and Risks

The filing notes the release of a corporate presentation (Exhibit 99.2) which may contain forward-looking statements, guidance, or management commentary. However, the text of the 8-K itself does not summarize specific outlooks, risks, contingencies, or unusual items. It explicitly states that the information in the exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific Q3 2019 revenue, net income, and cash flow figures.
  • Examine Exhibit 99.2 (Investor Presentation) for management's guidance, strategic outlook, and risk factors.
  • Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
  • Confirm the trading symbol (CDXC) and exchange (Nasdaq Capital Market) for accurate market data retrieval.